- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04538079
Non-invasive Objective Assessment of Hemodynamics in Preterm Neonates (NOAH)
Non-invasive Objective Assessment of Hemodynamics in Preterm Neonates - the NOAH Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Understanding neonatal hemodynamics is key to neonatal care. Despite decades of research, uncertainty continues as to how best assess impaired hemodynamics.
Hypotension defined by a low Mean Arterial Blood Pressure (MABP) remains a common issue in preterm infants, affecting up to 30% of extremely preterm infants.
It is common to focus only on MABP thus neglecting the complex and dynamic (patho)physiology that may be present in newborn infants. Providing sufficient cellular oxygenation is the primary task of the circulatory system and different factors may compromise it. In this prospective observational study the investigators will examine various forms of objective non-invasive continuous hemodynamic monitoring methods in very preterm infants
- For feasibility of non-invasive CO measurement (first 20 patients)
- For reproducibility and correlation of this measurement and ECHOcardiography (first 40 echocardiographic examinations)
- For prediction of therapy response.
- For correlation with clinical definitions of hypotension/hypoperfusion
- For prediction of later clinical problems/complications of prematurity and impaired hemodynamic status.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Christoph E Schwarz, MD
- Phone Number: +353 21 4205049
- Email: christoph.schwarz@ucc.ie
Study Contact Backup
- Name: Jean Conway
- Email: j.conway@ucc.ie
Study Locations
-
-
-
Cork, Ireland
- Neonatal Unit Cork University Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Neonates of 23 weeks 0 days to 31 weeks 6 days
- NIRS/non-invasive Cardiac Output - device available
- Parental Informed Consent
Exclusion Criteria:
- Congenital anomalies
- Major cardiac defects
- Hydrops
- Parents decline to consent to the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Feasibility/Accuracy/Reproducibility
The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
|
Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
|
Prediction of Circulatory Failure
Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
|
Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Outcome of Circulatory Failure
Time Frame: 14 days
|
Correlation of clinical, laboratory, conventional and multimodal non-invasive monitoring and/or a combination of variables with ultrasound abnormality (IVH grade 3 - 4/any IVH) or death within the first two weeks of life.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of non-invasive Cardiac Output Monitoring and Pulsatility Index
Time Frame: 48 hours
|
The proportion of infants in whom a continuous recording of non-invasive cardiac output (CO) and perfusion index (PI) analysis was obtained for at least 24 hours during the first 48 hours after birth with a good signal quality index
|
48 hours
|
Reproducibility of absolute left ventricular cardiac output estimated by echocardiography compared to cardiac output estimated by non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Reproducibility of cardiac output estimates by non-invasive Cardiac Output compared to echocardiographic examinations will be performed using absolute left ventricular output [mL/min].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of left ventricular cardiac output indexed to bodyweight estimated by echocardiography compared to cardiac output estimated by non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Reproducibility of cardiac output estimates by non-invasive Cardiac Output compared to echocardiographic examinations will be performed using left ventricular output indexed to bodyweight [mL/kg bodyweight/min].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of left ventricular stroke volume estimated by echocardiography compared to cardiac output estimated by non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Reproducibility of left ventricular stroke volume estimates by non-invasive Cardiac Output compared to echocardiographic examinations will be performed using stroke volume [mL].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of absolute right ventricular cardiac output indexed to bodyweight estimated by echocardiography compared to cardiac output estimated by non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Reproducibility of absolute cardiac output estimated by non-invasive Cardiac Output Monitoring compared to echocardiographic examinations will be performed using right ventricular output [mL/min].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of right ventricular cardiac output indexed to bodyweight estimated by echocardiography compared to estimation by non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Reproducibility of relative right ventricular cardiac output estimates by non-invasive Cardiac Output Monitoring compared to echocardiographic examinations will be performed using right ventricular output indexed to bodyweight [mL/kg bodyweight/min].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of left ventricular systolic time interval ratio estimated by non-invasive Cardiac Output Monitoring compared to echocardiography
Time Frame: 48 hours
|
Reproducibility of left ventricular systolic time interval ratio estimates by non-invasive Cardiac Output-Monitoring and echocardiographic examinations will be compared using left ventricular pre-ejection period to left ventricular output time ratio [no unit].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of absolute superior vena cava flow estimated by non-invasive Cardiac Output Monitoring compared to estimation by echocardiography
Time Frame: 48 hours
|
Cardiac output estimates of non-invasive Cardiac Output-Monitoring and echocardiographic examinations will be compared using absolute superior vena cava flow [mL/min].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Reproducibility of superior vena cava flow indexed to bodyweight estimated by non-invasive Cardiac Output Monitoring compared to estimation by echocardiography
Time Frame: 48 hours
|
Cardiac output estimates of non-invasive Cardiac Output-Monitoring and echocardiographic examinations will be compared using superior vena cava flow indexed to bodyweight [mL/kg bodyweight/min].
The Investigators will use Bland-Altman analysis (Bland-Altman plots, Repeatability coefficient.
Repeatability Index will be used for between parameter comparison.
|
48 hours
|
Correlation of non-invasive Cardiac Output Monitoring with echocardiography
Time Frame: 48 hours
|
CO-Monitoring and echocardiography will be analysed for correlation using correlation coefficient analysis pairwise for left and right ventricular output indexed to bodyweight [mL/kg bodyweight/min], left ventricular pre-ejection period to left ventricular output time ratio and Superior Vena Cava-flow indexed to bodyweight [mL/kg bodyweight/min].
|
48 hours
|
Prediction of response to volume/red-blood cell transfusion by Corrected Flow Time estimated with non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Treatment Responsiveness (Volume and/or red blood cells responsiveness) using trend analysis within Corrected Flow Time (FTC [ms]) for volume responsiveness including a receiver operating characteristic analysis for infants who received volume and/or red blood cells during the study period.
(Comparison of 20min mean as baseline before, during and 20min after treatment.
Response is defined as normalization of the above mentioned physiological parameters within 20 minutes after receiving treatment.
|
48 hours
|
Prediction of response to volume/red-blood cell transfusion by St roke Volume Variation estimated with non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Treatment Responsiveness (Volume and/or red blood cells responsiveness) using trend analysis within Stroke Volume Variation (SVV) for volume responsiveness including a receiver operating characteristic analysis for infants who received volume and/or red blood cells during the study period.
(Comparison of 20min mean as baseline before, during and 20min after treatment.
Response is defined as normalization of the above mentioned physiological parameters within 20 minutes after receiving treatment.
|
48 hours
|
Prediction of Prediction of response to inotropes by non-invasive Cardiac Output Monitoring response to therapy by non-invasive Cardiac Output Monitoring
Time Frame: 48 hours
|
Treatment Responsiveness (Inotrope) using trend analysis within left ventricular cardiac output indexed to bodyweight [ml/kg bodyweight/min] for inotrope responsiveness including a receiver operating characteristic analysis for infants who received inotropes during the study period.
(Comparison of 20min mean as baseline before, during and 20min after initiation of inotrope treatment.
Response is defined as normalization of the above mentioned physiological parameters within 20 minutes after receiving treatment.
|
48 hours
|
Correlation with definitions of hypotension
Time Frame: 48 hours
|
Correlation of multimodal non-invasive monitoring with commonly used definitions of hypotension (Mean Arterial Blood Pressure MABP below 30mmHG and/or MABP below gestational age in weeks)
|
48 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Burden of clinical suspicion indicating Circulatory Insufficiency
Time Frame: 48 hours
|
Onset and duration of clinical suspicion of Circulatory Insufficiency in clinical examination (i.e.
skin colour, increased capillary refill time>3seconds) as documented in the clinical charts.
|
48 hours
|
Burden of Laboratory parameters indicating Circulatory Insufficiency
Time Frame: 48 hours
|
Onset and duration of circulatory insufficiency indicated by laboratory parameters (metabolic acidosis with pH<7,2 Lactate>3mmol/L not explainable by intrapartum complications)
|
48 hours
|
Burden and Onset of Hypotension indicating Circulatory Insufficiency
Time Frame: 48 hours
|
Time spend with Mean Arterial Blood Pressure (MABP) below 30mmHG and/or MABP below gestational age in weeks
|
48 hours
|
Burden of Cerebral Oxygenation indicating Circulatory Insufficiency
Time Frame: 48 hours
|
Time spend wit cerebral regional tissue Saturation (rcStO2) below a value of 60% and/or rcStO2/fraction of tissue oxygen extraction (rcFtO2E) below the infants median value-5%
|
48 hours
|
Burden of Low Cardiac Output indicating Circulatory Insufficiency
Time Frame: 48 hours
|
Time spend with Cardiac Output in the lower quartile of the Cohort.
|
48 hours
|
Burden of impaired cerebral Autoregulation
Time Frame: 48 hours
|
Time spend with pressure passivity of cerebral regional tissue oxygenation (MABP and or Pulse Pressure to rcStO2/rcFtO2E).
Adjusted mutual information and transfer entropy will be used to quantify coupling between MABP or pulse pressure and rcStO2 or rcFtO2E.
|
48 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Eugene M Dempsey, MD, UCC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ED001/19UCC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraventricular Hemorrhage
-
Sharp HealthCareEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Nanjing PLA General HospitalUnknownIntraventricular Hemorrhage, Endoscopic Intraventricular Evacuation Surgery, Extraventricular DrainageChina
-
Children's Hospital Medical Center, CincinnatiRecruitingIntraventricular HemorrhageUnited States
-
University of Rhode IslandNational Institute of Nursing Research (NINR); Brown University; Women and Infants...CompletedSepsis | Intraventricular HemorrhageUnited States
-
Icahn School of Medicine at Mount SinaiIRRASRecruiting
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingIntraventricular Hemorrhage of PrematurityUnited States
-
Mount Sinai Hospital, CanadaLondon Health Sciences Centre; Royal Alexandra Hospital; Foothills Medical CentreNot yet recruitingIntraventricular Hemorrhage of Newborn Grade 2 | Intraventricular Hemorrhage of Newborn Grade 3 | Intraventricular Haemorrhage Grade IVCanada
-
Albert Einstein College of MedicineUniversity of Pittsburgh; Brigham and Women's Hospital; Wake Forest University... and other collaboratorsWithdrawnIntraventricular Hemorrhage of PrematurityUnited States
-
Sharp HealthCareEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedIntraventricular HemorrhageUnited States
-
National Taiwan University HospitalCompletedNursing Caries | Intraventricular Hemorrhage of PrematurityTaiwan
Clinical Trials on Multimodal objective non-invasive Monitoring
-
Increase-TechUniversity of Valladolid; Hospital Clínico Universitario de Valladolid; Sanidad...Completed
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedWomen With Abnormal Pap SmearsUnited States
-
Universitätsklinikum Hamburg-EppendorfCompletedBlood Pressure | Perioperative HypotensionGermany
-
University of MessinaSocieta Italiana Anestesia Analgesia Rianimazione e Terapia IntensivaRecruitingPostoperative Complications | Hemodynamic Monitoring | Blood Pressure DeterminationItaly
-
Biobeat Technologies Ltd.The Chaim Sheba Medical CenterRecruitingHeart Diseases | Blood PressureIsrael
-
Biobeat Technologies Ltd.Hadassah Medical OrganizationCompletedCongestive Heart Failure | Cardiac Output, Low | Cardiac Output, HighIsrael
-
VitalTracer Ltd.St. Justine's HospitalNot yet recruitingHypertension | Blood Pressure | Children | Intensive Care Unit | Oxygen Saturation | Vital Signs | NeonatalCanada
-
BiPS MedicalTel-Aviv Sourasky Medical Center; Carmel Medical CenterUnknownIntensive Care Unit Patients | Post-cardiac SurgeryIsrael
-
Biobeat Technologies Ltd.CompletedAcute Cardiac Event | Acute Cardiac Failure | Acute Cardiac Pulmonary EdemaIsrael